Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130331670> ?p ?o ?g. }
- W3130331670 endingPage "338" @default.
- W3130331670 startingPage "325" @default.
- W3130331670 abstract "Summary The manageable toxicity profile of obinutuzumab (GA101; G) alone or with chemotherapy in first‐line (1L; fit and non‐fit) and relapsed/refractory (R/R) patients with chronic lymphocytic leukaemia (CLL) was established in the primary analysis of the Phase IIIb GREEN trial (Clinicaltrials.gov: NCT01905943). The final analysis (cut‐off, 31 January 2019) is reported here. Patients received G (1000 mg) alone (G‐mono; fit and non‐fit patients) or with chemotherapy [fludarabine and cyclophosphamide (FC; fit patients); chlorambucil (non‐fit patients); bendamustine (any patient)]. Study endpoints were safety (primary) and efficacy (secondary). Subgroup analyses were performed on prognostic biomarkers in 1L CLL. Overall, 630 patients received 1L and 341 received R/R CLL treatment. At the final analysis, no new safety signals were observed [Grade ≥ 3 adverse events (AEs): 1L 82·7%, R/R 84·5%; serious AEs: 1L 58·1%, R/R 62·5%]. Neutropenia (1L 50·5%, R/R 53·4%) and thrombocytopenia (1L 14·6%, R/R 19·1%) were the most common Grade 3–5 AEs. G‐mono‐, G‐bendamustine and G‐FC‐treated patients with unmutated immunoglobulin heavy chain trended towards shorter progression‐free survival. Achievement of minimal residual disease negativity was greatest in 1L patients treated with G‐FC. In this final analysis of the GREEN trial, the safety profile of G was consistent with current risk management strategies. Biomarker analyses supported efficacy in the specific subgroups." @default.
- W3130331670 created "2021-03-01" @default.
- W3130331670 creator A5009431453 @default.
- W3130331670 creator A5011154715 @default.
- W3130331670 creator A5013551807 @default.
- W3130331670 creator A5015865081 @default.
- W3130331670 creator A5019866348 @default.
- W3130331670 creator A5020466742 @default.
- W3130331670 creator A5025985392 @default.
- W3130331670 creator A5027648948 @default.
- W3130331670 creator A5028727344 @default.
- W3130331670 creator A5040157636 @default.
- W3130331670 creator A5045917230 @default.
- W3130331670 creator A5054008156 @default.
- W3130331670 creator A5060087119 @default.
- W3130331670 creator A5061516043 @default.
- W3130331670 creator A5063193304 @default.
- W3130331670 creator A5076383652 @default.
- W3130331670 creator A5076735212 @default.
- W3130331670 creator A5084072193 @default.
- W3130331670 date "2021-02-19" @default.
- W3130331670 modified "2023-10-17" @default.
- W3130331670 title "Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study" @default.
- W3130331670 cites W1196637763 @default.
- W3130331670 cites W1843407789 @default.
- W3130331670 cites W1941121600 @default.
- W3130331670 cites W1981177563 @default.
- W3130331670 cites W2021628104 @default.
- W3130331670 cites W2024097666 @default.
- W3130331670 cites W2066357502 @default.
- W3130331670 cites W2086296392 @default.
- W3130331670 cites W2120319857 @default.
- W3130331670 cites W2140606816 @default.
- W3130331670 cites W2161184804 @default.
- W3130331670 cites W2295348655 @default.
- W3130331670 cites W2337485820 @default.
- W3130331670 cites W2345336553 @default.
- W3130331670 cites W2396328865 @default.
- W3130331670 cites W2548089616 @default.
- W3130331670 cites W2557262035 @default.
- W3130331670 cites W2624598927 @default.
- W3130331670 cites W2787916641 @default.
- W3130331670 cites W2791345134 @default.
- W3130331670 cites W2792666902 @default.
- W3130331670 cites W2799445517 @default.
- W3130331670 cites W2838088817 @default.
- W3130331670 cites W2890048426 @default.
- W3130331670 cites W2897636215 @default.
- W3130331670 cites W2901396567 @default.
- W3130331670 cites W2902460563 @default.
- W3130331670 cites W2902484351 @default.
- W3130331670 cites W2902706178 @default.
- W3130331670 cites W2907383716 @default.
- W3130331670 cites W2916146192 @default.
- W3130331670 cites W2948436219 @default.
- W3130331670 cites W2966190920 @default.
- W3130331670 cites W2970398865 @default.
- W3130331670 cites W3016538158 @default.
- W3130331670 cites W3049379535 @default.
- W3130331670 cites W4251009301 @default.
- W3130331670 doi "https://doi.org/10.1111/bjh.17326" @default.
- W3130331670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33605445" @default.
- W3130331670 hasPublicationYear "2021" @default.
- W3130331670 type Work @default.
- W3130331670 sameAs 3130331670 @default.
- W3130331670 citedByCount "6" @default.
- W3130331670 countsByYear W31303316702021 @default.
- W3130331670 countsByYear W31303316702022 @default.
- W3130331670 countsByYear W31303316702023 @default.
- W3130331670 crossrefType "journal-article" @default.
- W3130331670 hasAuthorship W3130331670A5009431453 @default.
- W3130331670 hasAuthorship W3130331670A5011154715 @default.
- W3130331670 hasAuthorship W3130331670A5013551807 @default.
- W3130331670 hasAuthorship W3130331670A5015865081 @default.
- W3130331670 hasAuthorship W3130331670A5019866348 @default.
- W3130331670 hasAuthorship W3130331670A5020466742 @default.
- W3130331670 hasAuthorship W3130331670A5025985392 @default.
- W3130331670 hasAuthorship W3130331670A5027648948 @default.
- W3130331670 hasAuthorship W3130331670A5028727344 @default.
- W3130331670 hasAuthorship W3130331670A5040157636 @default.
- W3130331670 hasAuthorship W3130331670A5045917230 @default.
- W3130331670 hasAuthorship W3130331670A5054008156 @default.
- W3130331670 hasAuthorship W3130331670A5060087119 @default.
- W3130331670 hasAuthorship W3130331670A5061516043 @default.
- W3130331670 hasAuthorship W3130331670A5063193304 @default.
- W3130331670 hasAuthorship W3130331670A5076383652 @default.
- W3130331670 hasAuthorship W3130331670A5076735212 @default.
- W3130331670 hasAuthorship W3130331670A5084072193 @default.
- W3130331670 hasBestOaLocation W31303316702 @default.
- W3130331670 hasConcept C126322002 @default.
- W3130331670 hasConcept C141071460 @default.
- W3130331670 hasConcept C143998085 @default.
- W3130331670 hasConcept C197934379 @default.
- W3130331670 hasConcept C2776694085 @default.
- W3130331670 hasConcept C2776755627 @default.
- W3130331670 hasConcept C2777063308 @default.
- W3130331670 hasConcept C2777607594 @default.
- W3130331670 hasConcept C2777866208 @default.